

IN THE CLAIMS

Please amend the claims in accordance with the following Listing of Claims, which replaces all previous Listings of Claims in this case:

Listing of claims:

1. (Currently amended) A method for treating a subject for a condition mediated by eotaxin which comprises generating an active immune response in the subject to human eotaxin by immunizing the subject with an immunogenic composition comprising eotaxin, ~~or a portion a~~ peptide comprising a 4 to 50 residue fragment of eotaxin, bound to an immunogenic carrier, wherein the immunogenic carrier is a protein toxoid molecule, wherein the condition mediated by eotaxin is selected from asthma, allergy or allergic disease, and wherein the subject is a human.
2. (Previously amended) The method of claim 1 wherein the condition mediated by eotaxin is asthma.
3. (Previously amended) The method of claim 1 wherein the active immune response comprises generating autoantibodies in the subject which bind to human eotaxin at a level sufficient to neutralize the effect of eotaxin in mediating the condition.
4. (Previously amended) The method of claim 1, which comprises immunizing the subject with an immunogenic composition, which generates antibodies in the subject, which bind to human eotaxin.
5. (Currently amended) The method of claim ~~4~~ 1 ~~wherein the immunogenic composition comprises a portion of eotaxin bound to an immunogenic carrier~~ the protein toxoid molecule is

selected from diphtheria toxoid (DT), tetanus toxoid (TT), and keyhole limpet hemocyanin (KLH).

6. (Withdrawn) The method of claim 5 wherein the immunogenic carrier comprises a T-cell epitope and an eotaxin derived epitope.
7. (Withdrawn) The method of claim 6 wherein the immunogenic composition comprises an immunogenic analog of the eotaxin.
8. (Withdrawn) The method of claim 4 wherein the immunogenic composition is a DNA vaccine.
9. (Withdrawn) An immunogenic composition comprising eotaxin or a peptide fragment thereof coupled to an immunogenic protein carrier.
10. (Withdrawn) The immunogenic composition of claim 9 comprising a T-cell epitope and an epitope derived from eotaxin.
11. (Withdrawn) The immunogenic composition of claim 9 comprising eotaxin or a portion thereof conjugated to an immunogenic carrier derived from DT, TT or KLH.
12. (Withdrawn) A method of producing the composition of claim 9 or 11, which comprises conjugating the eotaxin or a portion thereof to the immunogenic carrier.
13. (Withdrawn) A pharmaceutical formulation for use as a therapeutic vaccine comprising the immunogenic composition of claim 9, a pharmaceutically acceptable adjuvant and a pharmaceutically acceptable vehicle.
14. (Withdrawn) The immunogenic composition of claim 9 comprising a peptide sequence selected from the peptide sequences set forth in SEQ ID Nos. 1-38 and 42-61 or mixtures thereof.
15. (Withdrawn) A DNA vaccine that encodes a peptide, which generates an immune response to eotaxin.

16. (Newly presented) The method of claim 1 wherein a peptide comprising a 4 to 50 residue fragment of eotaxin is bound to the carrier, and wherein the peptide comprising a 4 to 50 residue fragment of eotaxin is selected from the group consisting of one or more of the peptides of SEQ ID NOS 2-38 and 42-61.

17. (Newly presented) The method of claim 1 wherein the immunogenic composition is administered in combination or association with a vaccine adjuvant.

18. (Newly presented) The method of claim 17 wherein the vaccine adjuvant is a water-in-oil emulsion.